Financial Performance - The company's operating revenue for 2022 was ¥1,400,737,343.44, representing a 32.99% increase compared to ¥1,053,235,426.39 in 2021[20]. - The net profit attributable to shareholders for 2022 was ¥178,745,385.35, a 50.92% increase from ¥118,438,152.08 in 2021[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥149,067,554.85, up 74.66% from ¥85,345,120.37 in 2021[20]. - The company's total assets at the end of 2022 were ¥4,455,360,858.16, a 36.71% increase from ¥3,259,000,827.99 at the end of 2021[20]. - The net assets attributable to shareholders at the end of 2022 were ¥3,064,751,877.97, reflecting a 64.01% increase from ¥1,868,651,254.39 at the end of 2021[20]. - The basic earnings per share for 2022 was ¥0.29, an increase of 38.10% compared to ¥0.21 in 2021[20]. - The weighted average return on equity for 2022 was 7.76%, up from 6.48% in 2021[20]. - The company achieved a total revenue of 1.4 billion yuan in 2022, with the natural sweetener business contributing 889 million yuan, becoming the main driver of revenue growth[48]. - In 2022, the company achieved total revenue of CNY 1,400.74 million, a year-on-year increase of 32.99%, and a net profit attributable to shareholders of CNY 178.75 million, up 50.92% from 2021, marking historical highs for both revenue and profit[62]. Cash Flow and Investments - The cash flow from operating activities for 2022 was negative at -¥258,422,111.78, a decline of 1,084.84% compared to ¥26,240,101.96 in 2021[20]. - The net cash flow from operating activities turned negative at -¥258,422,111.78, a significant decline from the previous year's positive cash flow[88]. - Investment cash flow net decreased by 189.77%, mainly due to an increase in investment of CNY 183 million from participating in the equity offering of Guilin Bank[89]. - Financing cash flow net increased by 15,337.09%, primarily due to net proceeds of CNY 961 million from a private placement[89]. - The company raised a total of RMB 967,999,997.25 through a non-public offering of 165,470,085 shares at a price of RMB 5.85 per share[104]. - The company temporarily supplemented working capital with RMB 498,500,000 from the raised funds, and RMB 400,000,000 was used for cash management[104]. Market and Industry Insights - The global plant extract market size in 2022 was approximately $34.4 billion, with a significant portion of the demand coming from the food and beverage sector, which accounts for nearly 50% of the market[31]. - The global plant extract market is expected to reach a market size of $59.4 billion by 2025, driven by increasing consumer demand for natural and healthy products[32]. - The company is the first listed entity in the domestic plant extract industry, recognized as a national-level specialized and innovative small giant enterprise, and a national-level green factory[38]. - The company ranks among the top three global suppliers of natural sweeteners, with a strong production and sales capability in stevia and monk fruit extracts[44]. - The natural sweetener market is expanding rapidly, with steviol glycosides expected to exceed $1.6 billion by 2028, driven by consumer demand for natural and sugar-free options[120]. Research and Development - The company has obtained 119 invention patents by the end of the reporting period, reflecting its strong focus on research and development[47]. - The company has established a research and development team led by returnee PhDs and set up a Plant Science Innovation Center to enhance its technological capabilities[152]. - The company is actively developing new products and technologies, including the microbial synthesis technology for natural sweeteners, to enhance its product value[52]. - The company is focusing on upgrading existing products through new technologies and equipment, aiming to accelerate the development and commercialization of synthetic biology technologies[152]. Corporate Governance - The company emphasizes risk-oriented principles in its internal control system to effectively mitigate operational risks[192]. - The company has established a complete governance structure with a board of directors, supervisory board, and various committees, ensuring independent decision-making and oversight[161]. - The board of directors consists of 7 members, including 3 independent directors, complying with legal requirements[160]. - The company has revised and improved 20 governance documents to enhance its internal control and governance structure[159]. Social Responsibility - The company provided a subsidy of 600 RMB per mu for the cultivation of monk fruit, covering 4,680 mu and benefiting 1,468 local farmers, with a total subsidy amount exceeding 2.7 million RMB[199]. - The company actively participated in social responsibility initiatives, including support for rural left-behind women in Guilin, providing care and living supplies[200].
莱茵生物(002166) - 2022 Q4 - 年度财报